Zyban ads
This article was originally published in The Tan Sheet
Executive Summary
Grey Advertising awarded the contract for Glaxo-Wellcome's Zyban (bupropion) Rx smoking cessation aid, the firm announced Nov. 30; Glaxo spent $54.5 mil. in advertising for the drug in 1998. Zyban is the most prescribed smoking cessation product on the market and competes with SmithKline Beecham's Nicoderm CQ transdermal patch, Nicorette gum, and McNeil Consumer Healthcare's Nicotrol patch. Private label OTC patches from Perrigo and Novartis recently have been approved by FDA as well. New York-based Grey also handles accounts for Whitehall-Robins' Centrum Herbals and Preparation H, and Novartis' recent athlete's foot Rx-to-OTC switch drug Lamisil AT
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning